Lymphoma & CLL Therapeutics

SYMPATICO study safety run-in: simultaneous ibrutinib plus venetoclax for R/R MCL

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma lacking therapeutic options that prolong...

Efficacy of ibrutinib plus venetoclax as first-line treatment in patients with CLL/SLL: Primary analysis from the MRD cohort of CAPTIVATE study

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, and...

What role is there for allogeneic SCT in the treatment of Hodgkin lymphoma?

During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021),...

Autologous vs allogeneic hematopoietic cell transplantation for the treatment of patients with PTCL-NOS or AITL who have failed first-line therapy

Patients with peripheral T-cell lymphoma (PTCL) that...

Orphan drug designation granted to zandelisib for follicular lymphoma

Follicular lymphoma (FL) is an indolent (or slowly progressing) B-cell lymphoma that represents 20‒30% of all non-Hodgkin...

FDA accepts new drug application for parsaclisib for R/R FL, MZL, and MCL

Non-Hodgkin lymphomas (NHLs) are a varied group of lymphatic cancers that may be indolent or aggressive, and while some...

Clinical factors predictive of POD24, a robust early clinical endpoint of poor survival in patients with FL

Follicular lymphoma (FL), the most common form of non-Hodgkin lymphoma and one that is...

Efficacy and safety of the triplet regimen obinutuzumab-atezolizumab-lenalidomide for patients with R/R follicular lymphoma

Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin’s...